---
title: "SARS-CoV-2 serology in HIV PrEP users during the COVID-19 pandemic: THE PREP-CO STUDY"
abbreviation: PrEP-Co
study_info:
  primary_outcomes: Seroconversion rate of SARS-CoV-2 antibody during one year of follow-up.
  secondary_outcomes: 
    - Pointprevalence of SARS-CoV-2 antibodies at baseline.
    - Pointprevalence of SARS-CoV-2 antibodies at follow-up visits.
    - correlation of the seroprevalence and/or seroconversion of SARS-CoV-2 positivity with sexual behaviour and other sexual transmitted diseases (STDs), such as syphilis, N. gonococcae, M. genitalium, C.trachomatis or HIV.
  funding_sources: Institutional budget, no external funding (budget of sponsor/PI)
  diagnostic_test:
    - company: YHLO Biotech
      product: SARS-CoV-2 Detection Kit
      address: Shenzhen, China
      antibody_classes:
        - IgG
        - IgM
recruitment:
  country:
    - Germany
  location:
    - place_name: Munich
      latitude: 48.1374859
      longitude: 11.6008283
  type: multicener diagnotic trial
  group: general population
study_numbers:
  study_population: 300
study_dates:
  sample_start: 2020-05-18
  sample_end: ongoing
  study_start: 2020-05-18
  study_first_results: 2021-03-31
study_pi:
  name: Christoph Spinner 
  institution: Rechts der Isar Hospital, Department for Internal Medicine II
  role: Professor
  email: christoph.spinner @ mri.tum.de
team:
  - role: Study Coordinator
    name: Simon Weidlich
    institution: Rechts der Isar Hospital, Department for Internal Medicine II
    position: Medical Director Assistant
    title: Priv.-Doz. Dr. 
---
To investigate to prevalence and seroconversion rate of SARS-CoV-2 antibodies in a German cohort of MSM using HIV PrEP, Germany, over a time period of one year following the first outbreak of the covid pandemic.

[DRKS link](https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022403)